WALTHAM, Mass. – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, issued the following statement regarding Affymetrix, Inc.’s (NASDAQ: AFFX) press release dated March 28, 2016:

JP Morgan is acting as financial advisor to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz is serving as legal counsel.“We are pleased that the Affymetrix board of directors has concluded that our merger agreement remains superior and continues to recommend that Affymetrix stockholders vote in favor of the transaction at the March 31, 2016, stockholder meeting,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “We are confident that Affymetrix stockholders will show their resounding support for our fully financed, all cash merger by voting in favor of our merger agreement. We look forward to completing the transaction immediately following the vote and welcoming our new Affymetrix colleagues to Thermo Fisher.”

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.